These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35326725)

  • 1. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.
    Kallergi G; Kontopodis E; Ntzifa A; Jordana-Ariza N; Karachaliou N; Pantazaka E; Charalambous HA; Psyrri A; Tsaroucha E; Boukovinas I; Koumarianou A; Hatzidaki D; Lianidou E; Georgoulias V; Rosell R; Kotsakis A
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326725
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
    Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).
    Pantazaka E; Ntzifa A; Roumeliotou A; Lianidou E; Georgoulias V; Kotsakis A; Kallergi G
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.
    Koinis F; Zafeiriou Z; Messaritakis I; Katsaounis P; Koumarianou A; Kontopodis E; Chantzara E; Aidarinis C; Lazarou A; Christodoulopoulos G; Emmanouilides C; Hatzidaki D; Kallergi G; Georgoulias V; Kotsakis A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
    Kim C; Xi L; Cultraro CM; Wei F; Jones G; Cheng J; Shafiei A; Pham TH; Roper N; Akoth E; Ghafoor A; Misra V; Monkash N; Strom C; Tu M; Liao W; Chia D; Morris C; Steinberg SM; Bagheri H; Wong DTW; Raffeld M; Guha U
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283064
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
    Ntzifa A; Kotsakis A; Georgoulias V; Lianidou E
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
    Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.
    Leonetti A; Cervati V; Minari R; Scarlattei M; Verzè M; Peroni M; Pluchino M; Bonatti F; Perrone F; Mazzaschi G; Cosenza A; Gnetti L; Bordi P; Ruffini L; Tiseo M
    Clin Lung Cancer; 2024 Dec; 25(8):e436-e445.e9. PubMed ID: 39198088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
    Messaritakis I; Nikolaou M; Politaki E; Koinis F; Lagoudaki E; Koutsopoulos A; Georgoulia N; Georgoulias V; Kotsakis A
    Lung Cancer; 2018 Oct; 124():270-278. PubMed ID: 30268472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
    Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment.
    Ma S; Shi M; Chen X; Wang Y; Yang Z; Lizaso A; Li M; Li H; Zhang L; Mao X; Xu X; Song Y
    Transl Lung Cancer Res; 2021 Jan; 10(1):326-339. PubMed ID: 33569316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based
    Xu J; Wu W; Wu C; Mao Y; Qi X; Guo L; Lu R; Xie S; Lou J; Zhang Y; Ding Y; Guo Z; Zhang L; Liang N; Chen P; Zhang C; Tao M; Yu Z; Geng H; Xu M; Shi M; Wang L; Guo W; Zhao J; Li J; Shi L; Zhang Y; Qin Z; Chen J; Liu J; Ren J; Yang Z; Pan X; Lv Z; Dong H; Zhang J; Ou J; Li Z; Kaji K; Wang Y; Wang J; Wang Z
    Transl Lung Cancer Res; 2021 Oct; 10(10):3888-3901. PubMed ID: 34858779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the impact of de novo and acquired
    Liu Y; Sun L; Xiong ZC; Sun X; Zhang SL; Ma JT; Han CB
    Onco Targets Ther; 2017; 10():2267-2279. PubMed ID: 28479857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer.
    Liang H; Huang J; Wang B; Liu Z; He J; Liang W
    J Thorac Dis; 2018 Apr; 10(Suppl 7):S838-S845. PubMed ID: 29780630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.